- Home
- LOBO vs BTAI Comparison
LOBO vs BTAI Comparison
Compare LOBO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOBO
- BTAI
- Stock Information
- Founded
- LOBO 2014
- BTAI 2017
- Country
- LOBO China
- BTAI United States
- Employees
- LOBO N/A
- BTAI N/A
- Industry
- LOBO
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- LOBO
- BTAI Health Care
- Exchange
- LOBO NYSE
- BTAI Nasdaq
- Market Cap
- LOBO 16.3M
- BTAI 18.1M
- IPO Year
- LOBO 2024
- BTAI 2018
- Fundamental
- Price
- LOBO $1.79
- BTAI $0.34
- Analyst Decision
- LOBO
- BTAI Buy
- Analyst Count
- LOBO 0
- BTAI 4
- Target Price
- LOBO N/A
- BTAI $2.81
- AVG Volume (30 Days)
- LOBO 14.9K
- BTAI 1.3M
- Earning Date
- LOBO 09-30-2024
- BTAI 03-11-2025
- Dividend Yield
- LOBO N/A
- BTAI N/A
- EPS Growth
- LOBO N/A
- BTAI N/A
- EPS
- LOBO 0.00
- BTAI N/A
- Revenue
- LOBO $19,469,766.00
- BTAI $2,276,000.00
- Revenue This Year
- LOBO $72.16
- BTAI $131.23
- Revenue Next Year
- LOBO $41.04
- BTAI $45.79
- P/E Ratio
- LOBO $1,496.48
- BTAI N/A
- Revenue Growth
- LOBO N/A
- BTAI 83.25
- 52 Week Low
- LOBO $1.35
- BTAI $0.30
- 52 Week High
- LOBO $4.70
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- LOBO N/A
- BTAI 42.14
- Support Level
- LOBO N/A
- BTAI $0.33
- Resistance Level
- LOBO N/A
- BTAI $0.39
- Average True Range (ATR)
- LOBO 0.00
- BTAI 0.06
- MACD
- LOBO 0.00
- BTAI -0.00
- Stochastic Oscillator
- LOBO 0.00
- BTAI 9.27
About LOBO LOBO EV TECHNOLOGIES LTD
Lobo EV Technologies Ltd is an electric vehicle manufacturer and seller company. It designs, develops, manufactures, and sells e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons, also provides automobile information and entertainment software development and design services to customers. The company operates in two operating segments: Electric vehicles and accessories sales which generates key revenue, and software royalties and development and design services. It generates all of its revenue within the People's Republic of China.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.